避免投资TXG的三大理由及一只替代股票推荐 - Finviz
3 Reasons to Avoid TXG and 1 Stock to Buy Instead - Finviz
生物技术与制药领域的最新动态
3 Reasons to Avoid TXG and 1 Stock to Buy Instead - Finviz
10x Genomics at Wolfe Research Healthcare: Navigating Challenges and Opportunities - Investing.com
10x Genomics (Nasdaq: TXG) Xenium Powers ASTRA Atlas of 2,000 Asia-Pacific Tumor Samples - Stock Titan
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium - PR Newswire
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - Nasdaq
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
10x Genomics (TXG): Assessing Valuation After Recent 34% Share Price Rise - simplywall.st
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - Yahoo Finance
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics Announces Chief Legal Officer Retirement - TipRanks
10x Genomics brings natural language to single-cell analysis through Claude integration - R&D World
10x Genomics on the “last mile” problem in single-cell analysis - R&D World
10x Genomics (NASDAQ:TXG) Nasdaq Futures Drives Data Biology - Kalkine Media
5 Insightful Analyst Questions From 10x Genomics’s Q3 Earnings Call - Markets Financial Content
5 Insightful Analyst Questions From 10x Genomics’s Q3 Earnings Call - Markets Financial Content
10x Genomics (TXG): Assessing Valuation After Strong Earnings, Upbeat Forecast and New Product Launch - Yahoo Finance
5 Insightful Analyst Questions From 10x Genomics’s Q3 Earnings Call - Yahoo Finance
Piper Sandler Maintains 10x Genomics (TXG) Neutral Recommendation - Nasdaq
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat - MSN